Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Starlight who wrote (1518)	6/17/2002 4:05:19 PM
From: ddl	Read Replies (4) \| Respond to of 1605

I wonder if any of the long term holders, knowledgeable about this Co. has read or can tell me the results of this report... >i>Health Technology Assessment Information Service, Windows on Medical Technology. "External counterpulsation for the treatment of stable angina." June 2000; 34:1-24. It seems some organizations have reservations about this procedure and I post the following quote for comments... Would love to read something more validating than this from third parties as this therapy is novel and appears simple. thanks Enhanced external counterpulsation (EECP) does not meet the following Technology Evaluation Center (TEC) criteria: The scientific evidence does not permit conclusions concerning the effect of the technology on health outcomes. It is impossible to determine if the technology improves health outcomes. It is impossible to determine if the technology is as beneficial as any established alternatives. The available literature does not validate reported improvement is attainable outside the investigational setting.